



COPE

Centre of Perinatal Excellence

Applied Skills in Perinatal Mental Health Assessment and Care

LESSON NOTEBOOK


Module 2 | Lesson 5

Pharmacotherapy and Management
of Severe Perinatal Mental Illness




Module 2: Lesson 5

Pharmacotherapy & Management of Severe Perinatal Mental Illness



Best Practice
COPE
Guideline



© COPE: Centre of Perinatal Excellence

cope.org.au

Medication – related Challenges

- Lack of understanding about the role of medications
- Patients told to come off medications
 - Can increase the rates of relapse
- Important to balance the risks and benefits on a case-by-case basis

© COPE: Centre of Perinatal Excellence

cope.org.au



Lesson 5 Overview

1. Moderate to severe PMH illness
2. Research findings
3. Psychotropic medication
4. Risk-benefit analysis of medication
5. Somatic interventions

© COPE: Centre of Perinatal Excellence

cope.org.au

Moderate to Severe
Anxiety and Depression



© COPE: Centre of Perinatal Excellencecope.org.au

Influencing Factors on Clinical Presentations

Possible supportive factors

- Increased sleep
- Access to support (practical / emotional)
- Increasing parenting confidence

Possible inhibitive factors

- Sleep deprivation
- Breast-feeding challenges
- Birth complications
- Unmet expectations
- Increased isolation

© COPE: Centre of Perinatal Excellencecope.org.au

Moderate to Severe Depression and Anxiety

In Pregnancy:

- Consider the use of **selective serotonin reuptake inhibitors (SSRIs)** as first-line treatment for moderate to severe depression and/or anxiety in pregnant women.

© COPE: Centre of Perinatal Excellencecope.org.au

Moderate to Severe Depression and Anxiety

In Pregnancy:

- Before choosing a particular antidepressant for pregnant women, consider the woman’s **past response** to antidepressant treatment, **obstetric history** (eg. other risk factors for miscarriage, preterm birth or postpartum haemorrhage) and any factors that may increase risk of adverse effects.

© COPE: Centre of Perinatal Excellence

cope.org.au

Moderate to Severe Depression and Anxiety

Postpartum:

- Use **SSRIs as first-line treatment** for moderate to severe depression in postnatal women.
- Before prescribing antidepressants to women who are breastfeeding, consider the infant’s health and gestational age at birth.

© COPE: Centre of Perinatal Excellence

cope.org.au

Moderate to Severe Depression and Anxiety

- Consider the **short-term use of benzodiazepines** for treating moderate to severe symptoms of anxiety while awaiting onset of action of an antidepressant in pregnant or postnatal women.
- Use caution** in repeated prescription of long-acting benzodiazepines around the time of birth.

© COPE: Centre of Perinatal Excellence

cope.org.au

Moderate to Severe Depression and Anxiety

- Use **caution** in prescribing **non-benzodiazepine hypnotics (z-drugs)** to pregnant women for insomnia.
- **Doxylamine**, a Category A drug in pregnancy, may be considered for use as a first-line hypnotic in pregnant women who are experiencing moderate to severe **insomnia**.

© COPE: Centre of Perinatal Excellence

cope.org.au


Moderate to Severe Depression and Anxiety

- Advise women with moderate to severe anxiety and depressive disorders **that psychological interventions are a useful adjunct**, usually once medications have become effective.

© COPE: Centre of Perinatal Excellence

cope.org.au

Guiding Principles
for Pharmacotherapy



Best Practice
Guideline

© COPE: Centre of Perinatal Excellence

cope.org.au

Guiding Principles - Pharmacotherapies

- Discuss the potential **risks and benefits** of pharmacological treatment in each individual case with the woman and, where possible, her significant other(s).

© COPE: Centre of Perinatal Excellence

cope.org.au

Guiding Principles - Pharmacotherapies

- Ensure that women are aware of the **risks of relapse** associated with stopping medication and that, if a medication is ceased, this needs to be done gradually and with advice from a mental health professional.

© COPE: Centre of Perinatal Excellence


cope.org.au

Management of Suicide Risk

- When a woman is identified as at risk of suicide (through clinical assessment and/or the EPDS), manage immediate risk, arrange for urgent mental health assessment and consider support and treatment options.

© COPE: Centre of Perinatal Excellence

cope.org.au



COPE Safety Plan

My triggers
What thoughts, feelings or situations trigger your suicidal thoughts or self-harm?

My warning signs
What thoughts, feelings or behaviours tell you that you are becoming more suicidal or at risk of self-harm?

My support network
Who can you talk to when you are feeling suicidal or at risk of self-harm?

My coping strategies
What can you do to help you feel better when you are feeling suicidal or at risk of self-harm?

My safety plan
What can you do to keep yourself safe when you are feeling suicidal or at risk of self-harm?

My emergency plan
What can you do if you are in a crisis and need help immediately?

© COPE: Centre of Perinatal Excellence
cope.org.au


Mother-Infant Interaction Difficulties

- For women who have or are recovering from postnatal depression and are experiencing mother-infant relationship difficulties, consider provision of or referral for individual **mother-infant** relationship interventions.

© COPE: Centre of Perinatal Excellence
cope.org.au

Clinical Considerations



- Case-by-case basis
- Weighing up the risks versus the benefits
- Referring to best practice guidelines



© COPE: Centre of Perinatal Excellence

cope.org.au

Management of Severe Mental Illness



© COPE: Centre of Perinatal Excellence

cope.org.au

Guiding Principles - Pharmacotherapies

- Ideally, treatment with psychoactive medications during pregnancy would involve close liaison between a treating psychiatrist or, where appropriate, the woman's GP, and her maternity care provider(s).
- In more complex cases, it is advisable to seek a second opinion from a perinatal psychiatrist.

© COPE: Centre of Perinatal Excellence

cope.org.au

Guiding Principles - Pharmacotherapies

- When exposure to psychoactive medications has occurred in the first trimester - especially with anticonvulsant exposures - pay particular attention to the 18-20 week ultrasound due to the increased risk of major malformation.

© COPE: Centre of Perinatal Excellence

cope.org.au

Guiding Principles - Pharmacotherapies

- Plan for pharmacological review in the early postpartum period for women who cease psychotropic medications during pregnancy.
- Arrange observation of infants exposed to psychoactive medications in pregnancy for the first three days postpartum.

© COPE: Centre of Perinatal Excellence

cope.org.au

Antipsychotic Medications

- Use antipsychotics for treating psychotic symptoms in pregnant women.
- Use caution when prescribing metabolic-inducing antipsychotics to pregnant women, due to the increased risk of gestational diabetes.

© COPE: Centre of Perinatal Excellence

cope.org.au

Antipsychotic Medications - Clozapine

- If considering the use of clozapine in pregnant women, seek specialist psychiatric consultation.
- Use clozapine with caution in women who are breastfeeding and monitor the infant's white blood cell count weekly for the first six months of life.

© COPE: Centre of Perinatal Excellence

cope.org.au

Antipsychotic Medications

- If women commence or continue antipsychotic treatment during pregnancy, monitor them for excessive weight gain and the development of gestational diabetes and refer them for advice on weight management as required.

© COPE: Centre of Perinatal Excellence

cope.org.au

Antipsychotic Medications - Preconception

- Given their teratogenicity, only consider prescribing anticonvulsants (especially valproate) to women of child-bearing age if effective contraception is in place.

© COPE: Centre of Perinatal Excellence

cope.org.au

Anticonvulsant Medications - Preconception

- Once the decision to conceive is made, if the woman is on valproate wean her off this over 2-4 weeks, while adding in high-dose folic acid (5 mg/day) which should continue for the first trimester.

© COPE: Centre of Perinatal Excellence

cope.org.au

Anticonvulsant Medications

- Use **great caution** in prescribing anticonvulsants as mood stabilisers for pregnant women and seek specialist psychiatric consultation when doing so.
- If prescribing lamotrigine to a woman who is breastfeeding, arrange **close monitoring of the infant** and specialist neonatologist consultation where possible.

© COPE: Centre of Perinatal Excellence


cope.org.au

Anticonvulsant Medications - Lithium


- If lithium is prescribed to pregnant women, ensure that maternal blood levels are **closely monitored** and that there is specialist psychiatric consultation.
- If lithium is prescribed to a pregnant woman, reduce the dose just prior to the onset of labour and aim to recommence treatment immediately after the birth at a pre-pregnancy dose.

© COPE: Centre of Perinatal Excellence


cope.org.au











Electroconvulsant Therapy - Antenatal

- In pregnant women, ECT should be only be undertaken in conjunction with close fetal monitoring (using cardiotocography to monitor fetal heart rate) and access to specialist maternal-fetal medical support.

Electroconvulsant Therapy - Postnatal

- Consider electroconvulsive therapy (ECT) when a postnatal woman with severe depression has not responded to one or more trials of antidepressants of adequate dose and duration.

© COPE: Centre of Perinatal Excellence

cope.org.au

Electroconvulsant Therapy - Postnatal

- Consider electroconvulsive therapy (ECT) as a first-line treatment where there is a high risk of suicide or high level of distress; when food intake is poor; and in the presence of psychotic or melancholic symptoms.

© COPE: Centre of Perinatal Excellence

cope.org.au

Transcranial Magnetic Stimulation

- Non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.

© COPE: Centre of Perinatal Excellence

cope.org.au


Early Warning Signs

- What are they
- Who identifies and how is this communicated
- Plans for action
- Who needs to be involved/engaged

© COPE: Centre of Perinatal Excellence

cope.org.au

Pharmacotherapy &
Management of Severe
Perinatal Mental Illness



© COPE: Centre of Perinatal Excellence

cope.org.au

Lesson 5: Recap

1. Consider SSRIs for moderate to severe anxiety and/or depression
2. Benzodiazapines - short-term use only
3. Non-Benzodiazapines - use cautiously in pregnancy

© COPE: Centre of Perinatal Excellence

cope.org.au

Lesson 5: Recap

- 4. Use antipsychotic medications with caution in pregnancy
- 5. Do not initiate clozapine in pregnancy and monitoring infant in breastfeeding women without specialist advice
- 6. Do not prescribe sodium valproate in pregnancy
- 7. Use great caution when prescribing anticonvulsants and lithium (avoid lithium in breastfeeding women)

© COPE: Centre of Perinatal Excellence

cope.org.au
